RNA editing for the treatment of alpha-1 antitrypsin deficiency
Nucleic Acids Research · 14.01.2026 · 54 (2)
DOI: 10.1093/nar/gkaf1518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 14.01.2026. Verfasst von Prashant Monian und 49 weiteren Autor:innen. Beteiligte Einrichtung: Wave Life Sciences, Cambridge, MA 02138, United States. Hauptthemen laut MEDLINE: RNA Editing, alpha 1-Antitrypsin, alpha 1-Antitrypsin Deficiency, Oligonucleotides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wave Life Sciences.
Abstract (Originalsprache)
Alpha-1 antitrypsin deficiency (AATD) is both a gain- and loss-of-function disease that impacts the liver and lung. Most severe cases result from a homozygous missense mutation in the SERPINA1 gene (Z mutation). While current therapies and those in development may ameliorate lung or liver disease, few are designed to address both. We have developed SERPINA1-994, an N-Acetylgalactosamine-conjugated chemically modified oligonucleotide that elicits adenine-to-inosine RNA editing using endogenous adenosine deaminases acting on RNA enzymes, to correct SERPINA1 Z transcripts. We show that SERPINA1-994 edits 50% of the Z transcript in hepatocytes of NSG-PiZ mice, which increases total serum AAT levels and induces the production of wild-type M-AAT protein. SERPINA1-994 addresses loss of AAT function in lung by increasing the neutrophil elastase inhibition capacity of mouse serum and gain of function in liver by correcting gene expression patterns, decreasing Z-AAT protein aggregation and decreasing inflammation. SERPINA1-994 relies on a clinically proven delivery technology and directs highly specific RNA rather than DNA editing with no bystander editing. Overall, these data suggest that SERPINA1-994 changes a ZZ homozygous state, which is associated with a high risk for AATD, to a low-risk MZ-like phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wave Life Sciences, Cambridge, MA 02138, United States.
ORCID-Profile: Jigar Desai, Chandra Vargeese
Förderung
- Wave Life Sciences
Zitieren
APA
Monian, P., Shivalila, C., Lu, G., Bowman, K., Briem, S., Bylsma, M., Byrne, M., Cannon, M., Chatterjee, A., Dallaire, M., Desai, J., Dufresne, J., Faraone, A., Favaloro, F., Friend, S., Ghosh, A., Godfrey, J., Hernandez, N., Huth, O., …, & Vargeese, C. (2026). RNA editing for the treatment of alpha-1 antitrypsin deficiency. Nucleic Acids Research, 54(2). https://doi.org/10.1093/nar/gkaf1518
Vancouver
Monian P, Shivalila C, Lu G, Bowman K, Briem S, Bylsma M, et al. RNA editing for the treatment of alpha-1 antitrypsin deficiency. Nucleic Acids Research. 2026;54(2). doi:10.1093/nar/gkaf1518
BibTeX
@article{Monian2026,
author = {Monian, Prashant and Shivalila, Chikdu and Lu, Genliang and Bowman, Keith and Briem, Stearne and Bylsma, Marissa and Byrne, Michael and Cannon, Megan and Chatterjee, Arindom and Dallaire, Morgan and Desai, Jigar and Dufresne, Jason and Faraone, Alyse and Favaloro, Frank and Friend, Stephen and Ghosh, Anamitra and Godfrey, Jack and Hernandez, Nidia and Huth, Olivia and Iwamoto, Naoki and Kawamoto, Tomomi and Lamattina, Anthony and Lemaitre, Muriel and Lindsey, Amber and Liu, Fangjun and Looby, Richard and Luu, Khoa and McGlynn, Andrew and Metterville, Jake and Paik, Ik-Hyeon and Pan, Qianli and Patil, Saurabh and Pu, Tom and Purcell-Estabrook, Erin and Ranade, Ashwini and Rheinhardt, Jeanette and Rossi, Jeff and Shimizu, Mamoru and Singh, Kuldeep and Standley, Stephany and Thomas, Carina and Tripathi, Snehlata and Yang, Hailin and Yordanoff, Ryan and Yin, Yuan and Yu, Hui and Narayanan, PadmaKumar and Kandasamy, Pachamuthu and Giangrande, Paloma H and Vargeese, Chandra},
title = {RNA editing for the treatment of alpha-1 antitrypsin deficiency},
journal = {Nucleic Acids Research},
year = {2026},
volume = {54},
number = {2},
doi = {10.1093/nar/gkaf1518}
}
EUVIMED